Niclosamide Formulations for the Treatment of Influenza Infections

用于治疗流感感染的氯硝柳胺制剂

基本信息

批准号：
10385194
负责人：
Gary Fujii
金额：
$ 29.85万
依托单位：
MOLECULAR EXPRESS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-08 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10385194
关键词：
2019-nCoV A549 Adenoviruses Adverse reactions Aerosols Animals Anions Antiviral Agents Body Weight decreased Bronchoalveolar Lavage Cell physiology Cells Coronavirus Data Dengue Virus Disease Dose Drug Modelings Drug Screening Effectiveness Endosomes Enterovirus Evaluation FDA approved Female Formulation Goals Hela Cells Hepatitis C virus Human In Vitro Infection Influenza Influenza A Virus, H1N1 Subtype Influenza A virus Inner mitochondrial membrane Lead Lethal Dose 50 Lipids Liposomes Lung Middle East Respiratory Syndrome Coronavirus Modeling Molecular Monitor Morbidity - disease rate Mus Nasopharynx National Heart, Lung, and Blood Institute Neonatal Respiratory Distress Patients Pharmaceutical Preparations Phase Premature Infant Preparation Production Property Proteins Protons Pulmonary Surfactants Reporting Research Respiratory Disease Respiratory distress Rhinovirus SARS coronavirus Site Small Business Innovation Research Grant Standardization Technology Testing Time Viral Viral Load result Viral Respiratory Tract Infection Virus Virus Diseases Zika Virus absorption aerosolized anti-viral efficacy clinical application delivery vehicle improved influenza infection influenza virus strain influenza virus vaccine influenzavirus inhibitor lipid nanoparticle lipophilicity men&apos s group nanomolar novel pH gradient pandemic disease peptide B professor prophylactic public health relevance respiratory virus surfactant vaccine formulation

项目摘要

Project Summary The principal goal of this project is to demonstrate that the FDA-approved anthelminthic drug, niclosamide, can be reformulated in a synthetic lung surfactant which can be aerosolized for the treatment of infections caused by respiratory viruses. The studies proposed in this SBIR Phase I application will be focused on testing this concept by suspending niclosamide loaded liposomes in our proprietary lung surfactant technology (Niclosurf) and testing candidate Niclosurf formulations in a mouse influenza challenge model. The effectiveness of Niclosurf as a treatment for respiratory viral infections caused by influenza will be evaluated.

项目摘要该项目的主要目标是证明FDA批准的驱虫药，烟酰胺可以在合成肺表面活性剂中进行重新制定，可以将其雾化以治疗由呼吸道病毒引起的感染。在此SBIR I期应用中提出的研究将集中在通过在我们的专有肺表面活性剂中悬挂烟酰胺，通过悬挂烟酰胺加载的脂质体来测试这一概念在小鼠流感挑战模型中，技术（Niclosurf）和测试候选候选Niclosurf公式。这将评估Niclosurf作为呼吸道病毒感染的治疗方法。